<div class="headers"><div>Table 1. Demographic and clinical characteristics at baseline</div><div>Table 2. Change from baseline: IND/GLY vs SFC in men and women with COPD</div><div>Figure 2 and Figure 3 The analyses were performed in the full analysis set from the FLAME study. Subjects who did not experience a COPD exacerbation were censored at the earlier date of last double-blind treatment + 1, death and final visit. Figure truncated after Week 52 (Day 365). b.i.d., twice daily; CI, confidence interval; HR, hazard ratio; IND/GLY, indacaterol/glycopyrronium 110/50 µg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 µg b.i.dDemographic and clinical characteristics at baseline for the randomized set has been presented. Data are presented as mean<U+2009>±<U+2009>SD unless otherwise stated. P-values are based on t-tests for continuous variables and chi-square tests (or Fisher’s exact test as appropriate) for categorical variables. aon a scale of 0–40, with higher scores indicating worse health status; bon a scale of 0–4, with higher scores indicating more severe dyspnea
BMI body mass index, CAT COPD assessment test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1<U+2009>s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting ß2-agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council, SD standard deviation</div><div>The analyses were performed in the full analysis set from the FLAME study, based on data availability. Data are presented as LSM. b.i.d. twice daily, CI confidence interval, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1<U+2009>s, IND/GLYindacaterol/glycopyrronium 110/50<U+2009>µg o.d., LSM least squares mean, MCID minimal clinically important difference, o.d. once daily, OR odds ratio, SFC salmeterol/fluticasone 50/500<U+2009>µg b.i.d., SGRQ-C St. George’s Respiratory Questionnaire for COPDMen</div><div>WomenMen n =<U+2009>2557</div><div>Women n =<U+2009>805</div><div>Pvalue</div><div>Treatment difference (IND/GLY vs SFC)</div><div>Time-to-first moderate/severe COPD exacerbations</div><div>HR (95% Cl): 0.79 (0.70-0.89); P< 0.001</div><div>HR (95% Cl): 0.76 (0.63-0.91); P= 0.004Age, years</div><div>65.2<U+2009>±<U+2009>7.7</div><div>62.6<U+2009>±<U+2009>7.6</div><div><<U+2009>0.001</div><div>Men</div><div>Pvalue</div><div>Women</div><div>Pvalue</div><div>Time-to-first all (mild/moderate/severe) COPD exacerbations.</div><div>HR (95% Cl): 0.86 (0.79-0.94); P= 0.001</div><div>HR (95% Cl): 0.80 (0.69-0.93); P = 0.005Duration of COPD, years</div><div>7.1<U+2009>±<U+2009>5.2</div><div>7.7<U+2009>±<U+2009>5.9</div><div>n =<U+2009>2550</div><div>n =<U+2009>804Current smoker, n (%)</div><div>946 (37.0)</div><div>387 (48.1)</div><div><<U+2009>0.001</div><div>Trough FEV1 (mL) (LSM [95% CI])</div><div>67 (51–84)</div><div><<U+2009>0.001</div><div>42 (12–71)Estimated number of pack years</div><div>43.6<U+2009>±<U+2009>22.5</div><div>36.0<U+2009>±<U+2009>18.5</div><div><<U+2009>0.001</div><div>SGRQ-C total score (LSM [95% CI])</div><div>-1.3 (-2.3– -0.4)</div><div>-1.1 (-2.8–0.7)Severity of COPD (GOLD 2015), n (%)</div><div>Proportion of patients with MCID (=4<U+2009>units) in SGRQ-C (OR [95% CI])</div><div>1.29 (1.09–1.54)</div><div>1.32 (0.96–1.83) Low risk and more symptoms (Group B)</div><div>589 (23.0)</div><div>233 (28.9)</div><div>Rescue medication use (puffs/day) (LSM [95% CI])</div><div>-0.27 (-<U+2009>0.43– -<U+2009>0.12)</div><div><<U+2009>0.001</div><div>-<U+2009>0.18 (-<U+2009>0.45–0.09) High risk and more symptoms (Group D)</div><div>1945 (76.1)</div><div>569 (70.7)Severity of airflow limitation (GOLD 2011–2014), n (%) Moderate (GOLD 2)</div><div>804 (31.4)</div><div>319 (39.6)</div><div><<U+2009>0.001 Severe (GOLD 3)</div><div>1506 (58.9)</div><div>448 (55.7) Very severe (GOLD 4)</div><div>222 (8.7)</div><div>35 (4.3)Pre-bronchodilator FEV1, L</div><div>1.1<U+2009>±<U+2009>0.3</div><div>0.8<U+2009>±<U+2009>0.2</div><div><<U+2009>0.001Post-bronchodilator FEV1, L</div><div>1.3<U+2009>±<U+2009>0.3</div><div>1.0<U+2009>±<U+2009>0.3</div><div><<U+2009>0.001Post-bronchodilator FEV1, % predicted</div><div>43.5<U+2009>±<U+2009>9.5</div><div>45.8<U+2009>±<U+2009>9.0</div><div><<U+2009>0.001Post-bronchodilator FEV1 reversibility, % of baseline value</div><div>22.2<U+2009>±<U+2009>16.0</div><div>22.9<U+2009>±<U+2009>16.2Post-bronchodilator FEV1/FVC, %</div><div>40.9<U+2009>±<U+2009>9.9</div><div>43.7<U+2009>±<U+2009>9.5</div><div><<U+2009>0.001Number of COPD exacerbations in the previous year, n (%) 1</div><div>2094 (81.9)</div><div>616 (76.5) =<U+2009>2</div><div>461 (18.0)</div><div>188 (23.4)CAT scorea</div><div>16.5<U+2009>±<U+2009>7.0</div><div>17.7<U+2009>±<U+2009>7.1</div><div><<U+2009>0.001mMRCb, n (%) Grade 0–1</div><div>4 (0.2)</div><div>1 (0.1) Grade 2</div><div>1838 (71.9)</div><div>574 (71.3) Grade 3</div><div>660 (25.8)</div><div>211 (26.2) Grade 4</div><div>55 (2.2)</div><div>19 (2.4)BMI (kg/m2)</div><div>25.7<U+2009>±<U+2009>4.9</div><div>26.3<U+2009>±<U+2009>6.0ICS use, n (%)</div><div>1382 (54.0)</div><div>511 (63.5)</div><div><<U+2009>0.001LAMA use, n (%)</div><div>1535 (60.0)</div><div>502 (62.4)LABA use, n (%)</div><div>1651 (64.6)</div><div>606 (75.3)</div><div><<U+2009>0.001</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>35</td>
<td style='border-bottom: 2px solid grey; text-align: left;'></td>
</tr>
</tbody>
</table>
